Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.

ABSTRACT:

Objective

To evaluate the safety and efficacy of cabozantinib combined with docetaxel.

Patients and methods

This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m² every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone.

Results

A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. D

SUBMITTER: Madan RA 

PROVIDER: S-EPMC8265825 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature